Advertisement
Canada markets close in 40 minutes
  • S&P/TSX

    22,023.82
    +151.86 (+0.69%)
     
  • S&P 500

    5,069.43
    +58.83 (+1.17%)
     
  • DOW

    38,484.62
    +244.64 (+0.64%)
     
  • CAD/USD

    0.7320
    +0.0019 (+0.26%)
     
  • CRUDE OIL

    83.40
    +1.50 (+1.83%)
     
  • Bitcoin CAD

    91,035.38
    +303.07 (+0.33%)
     
  • CMC Crypto 200

    1,435.68
    +20.92 (+1.48%)
     
  • GOLD FUTURES

    2,336.60
    -9.80 (-0.42%)
     
  • RUSSELL 2000

    2,006.34
    +38.87 (+1.98%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ

    15,708.24
    +256.94 (+1.66%)
     
  • VOLATILITY

    15.80
    -1.14 (-6.73%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     

Insider Watch: 2 CEOs Buying Shares

By monitoring insider activity, investors can gain insights into management's confidence in the company's direction and prospects.

And, of course, insiders have more in-depth knowledge about the company's operations, financials, and current standing. If they weren’t confident, why would they buy?

Recently, insiders of two companies – CVS Health CVS and Akamai Technologies AKAM – have been busy scooping up shares. What did the insiders see? Let’s take a closer look.

CVS Health

In early May, CEO Karen Lynch purchased approximately 14,000 CVS shares, with the transaction totaling nearly $1 million.

ADVERTISEMENT

CVS shares aren’t expensive, with the current 7.7X forward earnings multiple sitting nicely beneath the 9.9X five-year median and the Zacks Retail and Wholesale sector average.

The stock carries a Style Score of “A” for Value.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In addition, shares pay a solid dividend, currently yielding 3.6% annually with a sustainable payout ratio of 28% of earnings. The payout has grown by a modest 2.7% over the last five years.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The purchase comes on the heels of a better-than-expected quarterly print; CVS exceeded the Zacks Consensus EPS Estimate by 8% and delivered a 4.5% revenue surprise in its latest release on May 3rd.

Akamai Technologies

Akamai Technologies is a global provider of content delivery networks and cloud infrastructure services. Frank Leighton, CEO, has been on a big purchasing spree, buying roughly $200 thousand of AKAM shares just in May.

The stock presently sports a favorable Zacks Rank #2 (Buy), with earnings expectations modestly increasing across nearly all timeframes.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

AKAM shares got a solid boost in its latest release post-earnings, as we can see illustrated by the green arrow circled in the chart below.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Regarding the mentioned quarter, the company posted a double-beat, exceeding the Zacks Consensus EPS Estimate by 6% and posting a marginal revenue surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Bottom Line

Insiders have a longer-term holding horizon than most, a critical aspect that market participants should know. Nonetheless, seeing an insider step in and buy is always reassuring.

That’s precisely what the CEOs of both companies above – CVS Health CVS and Akamai Technologies AKAM – have done recently.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Akamai Technologies, Inc. (AKAM) : Free Stock Analysis Report

CVS Health Corporation (CVS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research